OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, September 01, 2016

(Interesting) Cancer Research in Australia 2016 to 2018 (chart includes ovarian)



canceraustralia

 Highlights 2016 to 2018
Funding to cancer research projects and programs

 
This review identified more than $252 million in funding to
589 individual research projects in the years 2016 to 2018.
The Australian Government is providing 74% of the identified
funding ($187 million).
95% of the identified research projects are being supported
by a single funding source.
Tumour-site specific research
Research funding to lung cancer, colon & rectum cancer,
lymphoma and cancers of the pancreas, oesophagus, mouth
and oropharynx, kidney, stomach, bladder, myeloma and bone
and connective tissue was low compared with their burden on
the Australian population (see Figure 1).
Research categories
Almost two thirds of funding is to the combined research
categories of Biology (28%) and Treatment (36%) (see Figure 2).
Etiology, Prevention and Cancer Control, Survivorship and
Outcomes Research receive 10%, 2% and 6% of funding,
respectively.
Translational Research
Translational research projects and programs in the categories
of Clinical, General, and Patient-oriented, each receive less than
10% of funding in 2016-2018 (see Figure 3).
Research collaborations
81% of research projects and programs have one or more
named collaborators (see Figure 4).
Of those projects with named collaborators, only 4% have
named international collaborators.

 

free event: Highlighting Welsh Cancer Research (South Wales) Sept 7th



News

  The event is free, but spaces are limited.  Reserve your space by emailing editor@ecancer.org.

ecancer is organising a meeting to celebrate the achievements of regional centres and groups working on cancer research and care in South Wales. This informal event is being held at the Life Sciences Hub in Cardiff on 7th September from 17.00 - 20.00 and will be chaired by Prof Malcolm Mason and hosted by Prof Gordon McVie.  After the talks there will be a networking session with refreshments.

The event is particularly special for ecancer because it is the first in series of meetings to mark our ten year anniversary of partnering with the global oncology community to provide free educational resources, events, news and open access primary research.

Editorial: Negative trials in ovarian cancer: is there such a thing as too much optimism? (popular article by # views)



Editorials: open access

(viewed 650 times)
 
Abstract
Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal. We also appeal against conducting large phase 3 trials that require significant resources without good phase 2 evidence for doing so.
Published: 17/08/2016

 Conclusion
As a profession, we must learn to call a spade a spade. Ineffective drugs must be acknowledged as such by the oncology community. Additionally, conducting large phase III trials entails a huge sum of financial, logistic and human resources which is not worth spending on questions that are foolish, ill-supported or over-powered at the outset. Care must be made to clarify if results are statistically or clinically significant, and above all caution should always be observed during the interpretation of clinical trial data. The true lessons of negative trials in ovarian cancer apply broadly to all fields of oncology.
 References
1. Siegel RL, Miller KD and Jemal A (2015) Cancer statistics, 2015 CA Cancer J Clin 65(1) 5–29
2. Stuart GC et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21(4) 750–5
3. Oza AM et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Lancet Oncology 16(8) 928–36

Review: The role of surgery in advanced epithelial ovarian cancer - OCEI



ecancermedicalscience - The open access journal from the European Institute of Oncology and the OCEI

AUA 2016: Reflections (Urology Times) comment re: ureteral perforation complications



Urology Times

 Lastly, I think the entire team who presented on Ureteral Perforation During Ureteroscopy was great, and they and the AUA deserve credit for highlighting this complication, which those of us who specialize in bread-and-butter urology risk on a daily basis.